EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment with CernitinTM of induced urinary bladder inflammation downregulates relevant pro-inflammatory biomarkers – an experimental in vivo rodent model

Nishtman Dizeyi, Celine Augé, Philippe Lluel, Magnus Grabe

Scandinavian Journal of Urology · 20.03.2026 · 61 · 58-63

DOI: 10.2340/sju.v61.45606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scandinavian Journal of Urology, online erschienen am 20.03.2026. Verfasst von Nishtman Dizeyi und 3 weiteren Autor:innen. Beteiligte Einrichtung: AB Cernelle, Ängelholm, Sweden. Hauptthemen laut MEDLINE: Cytokines, Cystitis, Plant Extracts. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Chronic inflammation of the urinary bladder is associated with the bladder pain syndrome. The treatment alternatives in humans are far from satisfactory and need further attention. Well-established preclinical models have shown that pro-inflammatory cytokines contribute to the progress of the inflammatory response behind pain and hyperalgesia. Previously presented results indicate that treatment with CernitinTM pollen extracts active pharmaceutical ingredients (APIs) (Cernitin GBX and Cernitin T60) significantly alleviated pain in cyclophosphamide-induced urinary bladder inflammation in a rodent model through downregulation of PGD2 and cyclooxygenase-2 (COX-2) mediators when compared to the vehicle alone. The objective was to extend the original study by exploring the correlation between the two APIs and cytokines expression and to identify a possible biomarker pattern. Material and method: The Olink® Target 48 Mouse Cytokine assay was conducted on the homogenised tissue extracts of the bladder wall with induced inflammation from a previous study to identify the potential impacts on protein biomarkers.

Results

The test revealed that treatment with the APIs significantly downregulated the cytokines interleukin (IL)-1α, IL-2, IL-4, IL-6, and with trend to significance the biomarkers IL-12 α, β, CCL4 and fibroblast growth factor 21 when administered in combination (GBX+T60) or each component alone, compared to vehicle controls.

Conclusion

This study identified seven cytokines that were significantly or markedly reduced. The results suggest that CernitinTM APIs impact a series of key pro-inflammatory biomarkers demonstrating an ability to restrain inflammation. Therefore, they warrant further investigation as potential therapeutic candidates

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytokinesCystitisPlant ExtractsAnimalsDown-RegulationBiomarkersMiceDisease Models, AnimalFemaleUrinary Bladder

Substanzen

BiomarkersCytokinesPlant Extracts

Autor:innen und Institutionen

  • AB Cernelle, Ängelholm, Sweden.
  • Urosphere, Toulouse, France.
  • Department of Translational Medicine, Lund University, Malmö, Sweden. magnus.grabe@med.lu.se.

Zitieren

APA

Dizeyi, N., Augé, C., Lluel, P., & Grabe, M. (2026). Treatment with CernitinTM of induced urinary bladder inflammation downregulates relevant pro-inflammatory biomarkers – an experimental in vivo rodent model. Scandinavian Journal of Urology, 61, 58-63. https://doi.org/10.2340/sju.v61.45606

Vancouver

Dizeyi N, Augé C, Lluel P, Grabe M. Treatment with CernitinTM of induced urinary bladder inflammation downregulates relevant pro-inflammatory biomarkers – an experimental in vivo rodent model. Scandinavian Journal of Urology. 2026;61:58-63. doi:10.2340/sju.v61.45606

BibTeX
@article{Dizeyi2026,
  author = {Dizeyi, Nishtman and Augé, Celine and Lluel, Philippe and Grabe, Magnus},
  title = {Treatment with CernitinTM of induced urinary bladder inflammation downregulates relevant pro-inflammatory biomarkers – an experimental in vivo rodent model},
  journal = {Scandinavian Journal of Urology},
  year = {2026},
  volume = {61},
  pages = {58--63},
  doi = {10.2340/sju.v61.45606}
}
Kostenlos starten →